mycotor-500
Mycotor 500 as Mycophenolate mofetil, also known as MMF a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Mycotor 500 is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. Mycophenolate mofetil has for the prophylaxis treatment of the transplant rejection approved by FDA in 1995. In addition, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases.
Composition
Mycophenolate Mofetil Tablets 500 mg
Mode of Action
Orally administered MMF is hydrolyzed by esterases in the intestine and blood to release mycophenolic acid (MPA), a potent, selective, noncompetitive inhibitor of the type 2 isoform of inosine monophosphate dehydrogenase (IMPDH) expressed in activated human T and B lymphocytes. The active metabolite of mycophenolate, mycophenolic acid, prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA.MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferential inhibition of IMPDH II.IMPDH normally transforms inosine monophosphate (IMP) to xanthine monophosphate (XMP), a metabolite contributing to the production of guanosine triphosphate (GTP).GTP is an important molecule for the synthesis of ribonucleic acid (RNA), deoxyribonucleic acid (DNA), and protein. As a result of the above cascade of effects, mycophenolate mofetil reduces de-novo production of guanosine nucleotides, interfering with the synthesis of DNA, RNA, and protein required for immune cell production.
Indications
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old
Dosage
1. A dose of 1g administered orally twice a day (daily dose of 2g ) is recommended for use in renal transplant patients, 2. Pediatrics (3 months to 18 years of age), 3. Patients with a body surface area of 1.25 m² to 1.5 m² may be dosed with Mycotor 500 tablets at a dose of 750 mg twice daily (1.5g daily dose), 4. Patients with a body surface area >1.5m² may be dosed with Mycotor 500 tablets at a dose of 1 g twice daily (2 g daily dose)
This information is for the registered medical practitioners only. Consult your medical practitioner before consuming the products.